Yini Zhu

Yini Zhu

Auto-generated profile, based on publicly available information

Yini Zhu

Department of Microbiology and Immunology, Medical School of Southeast University, Nanjing, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2024 in Cancer Research
Verified
Journal Article
Open access
PDF file
SMSean Murphy
Sean Murphy
SRSharif Rahmy
Sharif Rahmy
DGDailin Gan
Dailin Gan
GLGuoqiang Liu
Guoqiang Liu
YZYini Zhu
Yini Zhu
Xin LuXin Lu
Xin Lu
Resistance to immune checkpoint blockade (ICB) therapy represents a formidable clinical challenge limiting the efficacy of immunotherapy. In particular, prostate cancer poses a challenge for ICB therapy due to its immunosuppressive features. A ketogenic diet (KD) has been reported to enhance response to ICB therapy in some other cancer models. However, adverse effects associated with continuous KD were also observed, demanding better mechanistic understanding and optimized regimens for using KD as an immunotherapy sensitizer. In this study, we established a series of ICB-resistant prostate cancer cell lines and developed a highly effective strategy of combining anti-PD1 and anti-CTLA4 antibodies with histone deacetylase inhibitor (HDACi) vorinostat, a cyclic KD (CKD), or dietary supplementation of the ketone body β-hydroxybutyrate (BHB), which is an endogenous HDACi. CKD and BHB supplementation each delayed prostate cancer tumor growth as monotherapy, and both BHB and adaptive immunity were required for the antitumor activity of CKD. Single-cell transcriptomic and proteomic profiling revealed that HDACi and ketogenesis enhanced ICB efficacy through both cancer cell–intrinsic mechanisms, including upregulation of MHC class I molecules, and -extrinsic mechanisms, such as CD8+ T-cell chemoattraction, M1/M2 macrophage rebalancing, monocyte differentiation toward antigen-presenting cells, and diminished neutrophil infiltration. Overall, these findings illuminate a potential clinical path of using HDACi and optimized KD regimens to enhance ICB therapy for prostate cancer. Significance: Optimized cyclic ketogenic diet and 1,3-butanediol supplementation regimens enhance the efficacy of immune checkpoint blockade in prostate cancer through epigenetic and immune modulations, providing dietary interventions to sensitize tumors to immunotherapy.

10 March 2023 in Science Immunology
Verified
Journal Article
Closed access
YZYini Zhu
Yini Zhu
YZYun Zhao
Yun Zhao
JWJiling Wen
Jiling Wen
SLSheng Liu
Sheng Liu
THTianhe Huang
Tianhe Huang
Xin LuXin Lu
Xin Lu
The noninflamed microenvironment in prostate cancer represents a barrier to immunotherapy. Genetic alterations underlying cancer cell–intrinsic oncogenic signaling are increasingly appreciated for their role in shaping the immune landscape. Recently, we identified Pygopus 2 ( PYGO2 ) as the driver oncogene for the amplicon at 1q21.3 in prostate cancer. Here, using transgenic mouse models of metastatic prostate adenocarcinoma, we found that Pygo2 deletion decelerated tumor progression, diminished metastases, and extended survival. Pygo2 loss augmented the activation and infiltration of cytotoxic T lymphocytes (CTLs) and sensitized tumor cells to T cell killing. Mechanistically, Pygo2 orchestrated a p53/Sp1/Kit/Ido1 signaling network to foster a microenvironment hostile to CTLs. Genetic or pharmacological inhibition of Pygo2 enhanced the antitumor efficacy of immunotherapies using immune checkpoint blockade (ICB), adoptive cell transfer, or agents inhibiting myeloid-derived suppressor cells. In human prostate cancer samples, Pygo2 expression was inversely correlated with the infiltration of CD8 + T cells. Analysis of the ICB clinical data showed association between high PYGO2 level and worse outcome. Together, our results highlight a potential path to improve immunotherapy using Pygo2-targeted therapy for advanced prostate cancer.

6 October 2025 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
LYLeqian Ying
Leqian Ying
YZYini Zhu
Yini Zhu
LZLu Zhang
Lu Zhang
MJMin Ji
Min Ji
MWMeidan Wang
Meidan Wang
LLLin Liu
Lin Liu
Anti-angiogenic therapies are commonly employed in colon cancer management, yet many patients eventually develop resistance and experience disease progression. Vasculogenic mimicry (VM)—the formation of tumor-derived vessel-like networks—has been recognized as one mechanism contributing to this resistance, although the underlying details remain incompletely understood. Here, by integrating bioinformatic analyses of publicly available datasets and validating the results in patient samples (n = 157), we identified follistatin-like 3 (FSTL3) as a critical factor predominantly expressed in colon cancer-associated fibroblasts (CCAFs), with its expression strongly correlating with increased VM formation, intratumoral blood vessels, and poor prognosis. Single-cell RNA sequencing of tumors from VM and non-VM patients revealed that hypoxia drives FSTL3 expression in CCAFs, leading to extracellular matrix remodeling and enhancing cancer cell endothelial-like plasticity. Mechanistically, FSTL3 binds to transferrin receptor (TfR1), an iron-uptake receptor on cancer cells, thereby activating the TfR1/AKT/mTOR pathway and elevating VE-Cadherin to support endothelial-like transformation, VM, and metastatic progression. Notably, FSTL3-targeting antibodies (aFSTL3) effectively inhibited VM and angiogenesis in both in vitro and in vivo models, while the combination of aFSTL3 with bevacizumab produced synergistic suppression of neovascular-like structures and distant metastases. These findings demonstrate a pivotal role for FSTL3+ CCAFs in facilitating VM through TfR1-mediated signaling and offer a promising dual-target approach to overcome anti-angiogenic therapy resistance in colon cancer.

11 April 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
HZHaoge Zhang
Haoge Zhang
JMJia Miao
Jia Miao
LGLin Gao
Lin Gao
XYXuhong Yang
Xuhong Yang
ZYZhengcheng Yun
Zhengcheng Yun
JXJinbing Xie
Jinbing Xie
Bispecific immune cell engagers, particularly bispecific T-cell engagers, show limited efficacy in solid tumors such as glioblastoma (GBM) due to systemic toxicities, poor T cell infiltration, and restricted drug penetration. We develop PL@mBiME, a multifunctional lipid nanoparticle (LNP) platform that enables brain tumor–targeted delivery and sustained in vivo expression of mRNA encoding a bispecific macrophage engager (BiME). The BiME simultaneously targets ErbB2 on glioma cells and CD206 on M2 macrophages, reprogramming macrophages toward pro-inflammatory M1 phenotype while promoting macrophage–tumor cell bridging, enhancing tumor cell phagocytosis and antigen presentation. PL@mBiME incorporates pH-responsive charge reversal to improve tumor accumulation and lysosomal escape as well as glutathione-triggered release of surface-conjugated PD-L1 antibody to amplify anti-tumor immunity. Across multiple GBM models, this coordinated activation of innate and adaptive immunity induces tumor regression, prolongs survival, and generates durable immune memory without significant toxicity.

15 May 2026 in Science Advances
Verified
Journal Article
Open access
XYXuhong Yang
Xuhong Yang
HYHui Yang
Hui Yang
NXNuo Xu
Nuo Xu
YZYini Zhu
Yini Zhu
ZYZhengcheng Yun
Zhengcheng Yun
JXJinbing Xie
Jinbing Xie
Immune checkpoint inhibitors show promise in the treatment of melanoma brain metastases but are limited by CD73/adenosine axis-mediated immune evasion. Directly targeting CD73 with antibodies faces challenges due to poor blood-brain barrier permeability and metabolic regulators within the tumor microenvironment (IL-17-driven HIF-1α/VEGF-A). To overcome these barriers, we developed a nose-to-brain delivery platform using glycerol as a mucosal penetration enhancer to codeliver anti–IL-17 and anti-CD73 antibodies. Glycerol reversibly opened nasal epithelial tight junction proteins, enhancing the brain delivery of anti–IL-17 and anti-CD73 antibodies by 19.4- and 17.1-fold, respectively, while minimizing systemic exposure. Critically, anti–IL-17 attenuated CD73/adenosine axis-mediated immune evasion, significantly boosting anti-CD73 targeting efficacy. Ultimately, this combination promoted CD8 + T cell activation and residency, pro-inflammatory macrophage polarization, and reduced T reg cell infiltration, thereby eliciting a strong antitumor effect. Our results establish an efficient nose-to-brain delivery platform for macromolecules and propose a therapeutic strategy for tumors using anti–IL-17 to overcome TME-imposed limitations in CD73-targeted immunotherapy.

17 April 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
YZYang Zhang
Yang Zhang
JWJunfan Wei
Junfan Wei
CGChanchan Gao
Chanchan Gao
SFShenyang Feng
Shenyang Feng
HWHaiying Wang
Haiying Wang
LRLirong Ren
Lirong Ren
Background: Shugan Sanjie Decoction (SGSJ) is a commonly used Chinese medicine prescription for the treatment of uterine fibroids (UFs). However, there is still a lack of evidence for its effects and safety. To systematically assess the efficacy and safety of SGSJ in conjunction with Mifepristone [MFP] or Leuprolide acetate [LA] for the treatment of UFs, thereby providing a reference for clinical medication.Objective: To systematically assess the efficacy and safety of SGSJ in combination with MFP or LA for the treatment of UFs, thereby providing a basis for clinical medication decisions.Methods: Eight digital medical databases were systematically searched to identify randomized controlled trials (RCTs) evaluating the use of SGSJ combined with MFP or LA for the treatment of UFs. The search spanned from the inception of each database to July 2024. Risk of Bias (ROB) 2.0 and RevMan 5.3 software were utilized for systematic review and meta-analysis. Eligible studies comprised RCTs comparing SGSJ plus MFP or LA with MFP or LA alone. The primary outcome was the Clinical Effective Rate (CER). Secondary outcomes included (1) Uterine Fibroid Volume (UFV) (2), Uterine Volume (UV) (3), Serum Sex Hormone Levels [Follicle-Stimulating Hormone (FSH), Luteinizing Hormone (LH), Estradiol (E2), Progesterone (P)], and (4) Traditional Chinese Medicine Syndrome Scores (TSS).Results: The meta-analysis comprised 12 RCTs with 952 participants. The results of meta-analysis showed that the total effective rate of SGSJ or combined with MFP or LA in the treatment of UFs [RR = 1.26, 95% CI (1.19, 1.34), P < 0.00001], which was statistically significant compared with the MFP or LA group and superior to the MFP or LA group (P < 0.05).Conclusion: At present, there are evidence shows that SGSJ combined with MFP or LA improves CER, reduces UFV, and modulates sex hormone levels. However, due to the poor methodological quality and high heterogeneity of the included trials, our conclusions should be interpreted with caution. Future studies should prioritize rigorous RCTs with standardized treatment protocols, extended follow-up, and comprehensive safety assessments to identify SGSJ as a reliable treatment option for UFs.Systematic Review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024506017